Two Fibromyalgia Vitamin D intravention studies in Turkey:
successful weekly treatment with 50,000 IU
Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency - Nov 2016
Int J Rheum Dis. 2016 Nov 11. doi: 10.1111/1756-185X.12960. [Epub ahead of print]
- Overview Fibromyalgia or Chronic Fatigue and vitamin D
- Overview Pain and Vitamin D
- Less use of musculoskeletal pain drugs if get vitamin D – Feb 2015
- Fibromyalgia pain with trazodone reduced by 50 percent with weekly 50,000 IU of vitamin D – RCT Nov 2014
- Fibromyalgia pain reduced with vitamin D intervention that achieved 30-48 ng – RCT Feb 2014
- Chronic Pain reported 38 percent less often if supplemented with Vitamin D – meta-analysis Sept 2016
- Chronic Widespread Pain associated with Vitamin D under 10 ng – meta-analysis Oct 2015
- Fibromyalgia helped by Vitamin D – still not sure how much, and why - June 2016
Yilmaz R1, Salli A2, Cingoz HT3, Kucuksen S2, Ugurlu H2.
1Department of Physical Medicine and Rehabilitation, Yoncali Physical Medicine and Rehabilitation Hospital, Kutahya, Turkey.
2Department of Physical Medicine and Rehabilitation, Meram Medical School, Necmettin Erbakan University, Konya, Turkey.
3Department of Physical Medicine and Rehabilitation, Seydisehir State Hospital, Konya, Turkey.
The objective of this study is the evaluation of the effect of vitamin D replacement treatment on musculoskeletal symptoms and quality of life in patients with chronic widespread musculoskeletal pain (CWP) including fibromyalgia (FM) and vitamin D deficiency.
Patients with nonspecific CWP and vitamin D deficiency (25-OH D3 < 25 ng/mL) were included into the study. Replacement treatments of 50 000 IU/week oral vitamin D3 for 3 months were given to the patients. Patients were assessed pre- and post-treatment in terms of serum levels of Ca, P, alkaline phosphatase, 25-OH D3, severity of pain (visual analogue scale [VAS]-pain), severity of asthenia (VAS-asthenia), Beck Depression Inventory (BDI), quality of life scale (Short Form [SF]-36), tender point count (TPC), severity of waking unrefreshed, headache, tenderness on tibia, meeting the criteria of FM, and level of patient satisfaction.
Fifty-eight patients with a mean age of 36.9 ± 9.2 years were included into the study. 25-OH D3 levels of patients elevated from 10.6 ± 5.1 ng/mL to 46.5 ± 24.0 ng/mL after replacement treatment (P < 0.001).
Marked decrease in
- severity of waking unrefreshed, TPC, and BDI
and an evident increase in
- subgroups of SF-36
were established in patients after treatment (P < 0.001).
The number of FM+ patients was 30 (52%) before treatment and regressed to 20 (34%) after treatment (P = 0.013); 85% of patients stated satisfaction with the treatment.
Vitamin D replacement treatment in patients with nonspecific CWP has provided improvements in musculoskeletal symptoms, level of depression and quality of life of patients. Patients with CWP should be investigated for vitamin D deficiency.
PMID: 27860257 DOI: 10.1111/1756-185X.12960
Most of the Quality of life parameters were statistically improved by weekly 50,000 IU of vitamin D
Download the PDF from VitaminDWiki
This page was renamed June 2017 when the 2017 study was added